• VolitionRx highlighted an asset-light strategy centered on licensing Nu.Q technology, citing USD 23 million in licensing revenue to date.
• Q1 2026 revenue listed at about USD 1 million, with Nu.Q Vet positioned as a commercial anchor alongside recurring kit and component sales.
• Veterinary franchise update included worldwide Nu.Q Vet rollout, pricing as low as USD 35 per test to veterinarians with VolitionRx receiving USD 5-13 per test, with 76% systemic cancer detection at 97% specificity.
• Near-term catalysts included expected publication of feline lymphoma validation data that would trigger a USD 5 million contractual milestone payment, with Fujifilm Vet Systems launch on IDS i10 automated platform.
• Human pipeline focus included Nu.Q NETs for sepsis, with French government-backed DETECSEPS program financed at about USD 7.3 million and first patient targeted for Q3 2026, alongside preparations for reimbursement submissions and planned routine clinical use in France in 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.